Davide Ciardiello

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8055258/publications.pdf

Version: 2024-02-01

55 papers	1,513 citations	430874 18 h-index	361022 35 g-index
56 all docs	56 docs citations	56 times ranked	2090 citing authors

#	Article	IF	Citations
1	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. Cancer Treatment Reviews, 2019, 76, 22-32.	7.7	224
2	Clinical management of metastatic colorectal cancer in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2022, 72, 372-401.	329.8	167
3	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World Journal of Gastroenterology, 2017, 23, 4675.	3.3	91
4	Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. Clinical Cancer Research, 2014, 20, 3775-3786.	7.0	89
5	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer. JAMA Oncology, 2021, 7, 1529.	7.1	80
6	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. Molecular Cancer Therapeutics, 2019, 18, 845-855.	4.1	58
7	Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. Journal of Experimental and Clinical Cancer Research, 2019, 38, 41.	8.6	57
8	AXL is an oncotarget in human colorectal cancer. Oncotarget, 2015, 6, 23281-23296.	1.8	55
9	Implication of the Hedgehog pathway in hepatocellular carcinoma. World Journal of Gastroenterology, 2017, 23, 4330.	3.3	54
10	Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study. Clinical Cancer Research, 2021, 27, 2515-2522.	7.0	39
11	BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199297.	3.2	38
12	Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093608.	3.2	37
13	Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. Cancers, 2019, 11, 1504.	3.7	36
14	Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed?. Cancer Treatment Reviews, 2020, 86, 102023.	7.7	34
15	Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092521.	3.2	31
16	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open, 2018, 3, e000299.	4.5	29
17	Gut microbiota correlates with antitumor activity in patients with <scp>mCRC</scp> and <scp>NSCLC</scp> treated with cetuximab plus avelumab. International Journal of Cancer, 2022, 151, 473-480.	5.1	24
18	AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. European Journal of Cancer, 2020, 138, 1-10.	2.8	23

#	Article	IF	Citations
19	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. Clinical Cancer Research, 2015, 21, 4153-4164.	7.0	21
20	Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers, 2021, 13, 1941.	3.7	21
21	Baseline IFN-Î³ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. Scientific Reports, 2020, 10, 17626.	3.3	20
22	Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. Journal of Experimental and Clinical Cancer Research, 2019, 38, 236.	8.6	17
23	Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities. Vaccines, 2021, 9, 623.	4.4	17
24	Macrophage Migration Inhibitory Factor Is a Molecular Determinant of the Anti-EGFR Monoclonal Antibody Cetuximab Resistance in Human Colorectal Cancer Cells. Cancers, 2019, 11, 1430.	3.7	15
25	Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature. ESMO Open, 2019, 4, e000551.	4.5	15
26	Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. Oncotarget, 2017, 8, 67592-67604.	1.8	15
27	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives. International Journal of Molecular Sciences, 2022, 23, 820.	4.1	15
28	CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients. Frontiers in Oncology, 0, 12, .	2.8	14
29	Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 15.	8.6	13
30	Immunotherapy in advanced anal cancer: Is the beginning of a new era?. Cancer Treatment Reviews, 2022, 105, 102373.	7.7	12
31	Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania â€˜Luigi Vanvitelliâ€™. ESMO Open, 2020, 5, e000675.	4.5	11
32	Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day. Biomedicines, 2022, 10, 411.	3.2	11
33	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. Clinical Colorectal Cancer, 2021, 20, 227-235.	2.3	10
34	Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma. International Journal of Molecular Sciences, 2021, 22, 1166.	4.1	10
35	Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. Clinical Colorectal Cancer, 2022, 21, 141-148.	2.3	10
36	Insights into the role of gut and intratumor microbiota in pancreatic ductal adenocarcinoma as new key players in preventive, diagnostic and therapeutic perspective. Seminars in Cancer Biology, 2022, 86, 997-1007.	9.6	8

#	Article	IF	Citations
37	Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210968.	3.2	8
38	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update. Expert Review of Molecular Diagnostics, 2020, 20, 653-664.	3.1	7
39	Dual inhibition of TGFÎ² and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. Medical Oncology, 2021, 38, 24.	2.5	7
40	How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. Cancers, 2021, 13, 4719.	3.7	7
41	Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.. Journal of Clinical Oncology, 2019, 37, TPS731-TPS731.	1.6	7
42	Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. Journal of Experimental and Clinical Cancer Research, 2022, 41, 109.	8.6	7
43	Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR. Cancers, 2022, 14, 3053.	3.7	7
44	A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant. Medicine (United States), 2019, 98, e15759.	1.0	6
45	Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.. Journal of Clinical Oncology, 2021, 39, 3578-3578.	1.6	6
46	Critical review on the use and abuse of alcohol. When the dose makes the difference. Minerva Medica, 2020, 111, 344-353.	0.9	6
47	Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.. Journal of Clinical Oncology, 2020, 38, 4112-4112.	1.6	6
48	Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. Cancers, 2021, 13, 5715.	3.7	6
49	Light Alcohol Drinking and the Risk of Cancer Development: A Controversial Relationship. Reviews on Recent Clinical Trials, 2020, 15, 164-177.	0.8	4
50	Cutaneous Metastasis from Colorectal Cancer: Making Light on an Unusual and Misdiagnosed Event. Life, 2021, 11, 954.	2.4	3
51	Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New Results. Journal of Personalized Medicine, 2021, 11, 206.	2.5	2
52	Abstract 2627: Inhibition of TGFÎ² in colorectal cancer cells is associated with a compensatory activation of AXL and p38 MAPK signaling pathways. Cancer Research, 2019, 79, 2627-2627.	0.9	2
53	Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. Diagnostics, 2022, 12, 685.	2.6	1
54	Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer. Current Colorectal Cancer Reports, 2014, 10, 279-287.	0.5	0

#	Article	IF	Citations
55	Abstract 295: Synergism between oxaliplatin or irinotecan with the PARP inhibitor niraparib in a preclinical model of KRAS/BRAF mutated colorectal cancer is associated with MSI status. , 2019, , .		0